Size | Price | Stock | Qty |
---|---|---|---|
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Naproxen Sodium (formerly RS 3650; RS-3650; Naproxen natrium), an approved non-steroidal anti-inflammatory drug (NSAID), is a nonselective COX inhibitor for COX-1 and COX-2 with potential anti-inflammatory activity. It inhibits COX-1 and COX-2 with IC50s of 8.7 μM and 5.2 μM, respectively.
ln Vitro |
When absorbed, naproxen etemesil, a lipophilic, non-acidic, inactive prodrug, hydrolyzes to produce naproxen, which is pharmacologically active. One well-known nonsteroidal anti-inflammatory medication is naproxen. In intact cells, naproxen inhibits COX-1 and COX-2 approximately equipotently, with IC50 values of 2.2 μg/mL and 1.3 μg/mL, respectively[1].
|
||
---|---|---|---|
ln Vivo |
Naproxen reduces inflammation and inhibits fibrosis in a mouse model of lung fibrosis caused by bleomycin. Moreover, naproxen inhibits the production of the Smad3/4 complex and TGF-β levels[2]. It has been demonstrated that naproxen inhibits PGE2, pain, and fever time courses with potencies comparable to these (IC50=27, 40, and 13 μM)[3].
|
||
Animal Protocol |
|
||
References |
[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7.
[2]. Rosa AC, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther. 2014 Nov;351(2):308-16. [3]. Krekels EH, et al. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats |
Molecular Formula |
C14H13NAO3
|
|
---|---|---|
Molecular Weight |
252.24
|
|
CAS # |
26159-34-2
|
|
SMILES |
[Na+].O(C([H])([H])[H])C1C([H])=C([H])C2C([H])=C(C([H])=C([H])C=2C=1[H])[C@@]([H])(C(=O)[O-])C([H])([H])[H]
|
|
InChi Key |
CDBRNDSHEYLDJV-FVGYRXGTSA-M
|
|
InChi Code |
InChI=1S/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1
|
|
Chemical Name |
2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, sodium salt, (S)-
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.9645 mL | 19.8224 mL | 39.6448 mL | |
5 mM | 0.7929 mL | 3.9645 mL | 7.9290 mL | |
10 mM | 0.3964 mL | 1.9822 mL | 3.9645 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.